Glatiramer acetate

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Multiple sclerosis, ATC, Pain, Capsule, International, Spinal cord, Disease, PML, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, Antioxidant, European Medicines Agency, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Cell, Safety, Encephalitis, Anatomy, IIA, Optic nerve, Skin, Medical device

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Pharmaceutical, Health, Glatiramer acetate, Research, Executive, Natco Pharma, Pharmacy technician, DASH, Growth, NDC, Fine chemical

Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.

Key Points: 
  • Natco Pharma Limited, a research and development (R&D)-focused pharmaceutical company based in India, today announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.
  • As of January 2, all products marketed by the company will transition to the Natco Pharma USA label, with no changes to the current NDC Numbers.
  • Julie Trendowicz and Nick DiMaio, the former Executive Vice President and President of DASH, respectively, will assume the same roles under Natco Pharma USA.
  • “By acquiring DASH, Natco Pharma has gained a strategic presence in the United States, connecting us directly with our valued customers in this crucial market,” said Subba Rao Mente, Chief Executive Officer of Natco Pharma USA.

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023

Retrieved on: 
Tuesday, October 10, 2023
Congress, Mount Sinai, RMS, PPMS, NESS, Great America Committee, MS, Treatment, Multiple sclerosis, Safety, Principal, Conditional sentence, GA, Research, New Drug Application, Glatiramer acetate, Department of Neurology, Xuanwu hospital, Conference, Icahn School of Medicine at Mount Sinai, Patient, Pharmaceutical industry

Multiple sclerosis (MS) is a chronic disease requiring lifelong therapy.

Key Points: 
  • Multiple sclerosis (MS) is a chronic disease requiring lifelong therapy.
  • Glatiramer acetate (GA) long-acting injection (GA Depot) consists of extended-release GA, administered once every 28 days.
  • Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma said, “We are progressing with our New Drug Application for GA Depot for the treatment of RMS.
  • The ECTRIMS-ACTRIMS meeting is an important forum to share with the neurological and investor community that GA Depot may offer an effective treatment option to patients with relapsing forms of multiple sclerosis."

Kinimmune publishes results from a Phase I “Window of Opportunity” trial in patients with solid tumors

Retrieved on: 
Friday, March 3, 2023
Stem Cells, Biotechnology, Pharmaceutical, Surgery, Oncology, Health, Genetics, Clinical Trials, Nuclear Medicine Communications, FDA, Patient, Clinical trial, RNA-Seq, Sclerosis, King Abdulaziz University, University, Glatiramer acetate, Safety, Injection, Cancer, Neoplasm, Pharmaceutical industry

Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results from a Phase I trial in solid tumor patients.

Key Points: 
  • Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results from a Phase I trial in solid tumor patients.
  • The paper, titled “A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors,” was published in Translational Medicine Communications.
  • This work was conducted in collaboration with researchers at the University of Kansas Cancer Center and King Abdulaziz University.
  • In this open label study, 9 patients with resectable solid malignancies were treated with Copaxone®, the longest approved glatiramer acetate product.

IBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.

Retrieved on: 
Tuesday, December 13, 2022
Asthma, BVXV, Weizmann Institute of Science, Degenerative disease, IBN, Glatiramer acetate, University Medical Center, Season, DBP, News, Knowledge, Drug Quality and Security Act, Psoriasis, Infection, Research, Teva Pharmaceuticals, History, Social media, Reichmann, COVID-19, Max Planck Society, Pharmaceutical industry, BiondVax

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.

Key Points: 
  • The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.
  • Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.
  • The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series .
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors

Retrieved on: 
Wednesday, November 9, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, COO, National, Vaccine, Glatiramer acetate, Tumor microenvironment, National Cancer Institute, University of Kansas Medical Center, STTR, Children's Mercy Hospital, CpG, TLR9, King Abdulaziz University, Neoplasm, Ligation, Safety, Infection, Cory, Cancer, Lymph, CSO, University, Patient, Immune system, NCI, FDA, Pharmaceutical industry

The STTR program at NCI is designed to fuel small businesses on the cutting edge of innovation with nondilutive funding to de-risk and advance promising cancer interventions.

Key Points: 
  • The STTR program at NCI is designed to fuel small businesses on the cutting edge of innovation with nondilutive funding to de-risk and advance promising cancer interventions.
  • STTR grants from the NCI are highly selective and were awarded to just 15% of applicants in 2021.
  • Winning this award provides invaluable scientific validation in addition to the research funding, shared Cory Berkland, President and Co-founder of Kinimmune.
  • This award from the NCI will help Kinimmune continue the preclinical development of KIN-102, shared Nabil Alhakamy, COO and Co-Founder of Kinimmune.

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

Retrieved on: 
Wednesday, September 21, 2022
Multiple sclerosis, Safety, Injection, Department, Chief executive officer, Mount Sinai, MAPI, Sclerosis, Principal, Compliance, LCM, RMS, Icahn School of Medicine at Mount Sinai, Partnership, Glatiramer acetate, PPMS, Diabetes, Patient, MS, GA, Patient satisfaction, API, CEO, ARR, Department of Neurology, Xuanwu hospital, Medicine, NASDAQ, NESS, Â, GLOBE, IM, Patent, Pharmaceutical industry, Fine chemical, Viatris

The positive top-line efficacy results from the GA Depot 40 mg Phase III trial are an exciting step forward in our long-standing commitment to supporting the needs of the multiple sclerosis community.

Key Points: 
  • The positive top-line efficacy results from the GA Depot 40 mg Phase III trial are an exciting step forward in our long-standing commitment to supporting the needs of the multiple sclerosis community.
  • GA Depot is intended to be used for treatment of Relapsing forms of Multiple Sclerosis (RMS).
  • Mapi Pharma partnered with Viatris (NASDAQ: VTRS) for GA Depot in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis.
  • Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Xinteza Introduces Novel Key Enzyme to Solve Major Bottlenecks in Cannabinoid Biosynthesis

Retrieved on: 
Thursday, September 8, 2022
Enzyme, Research, CEO, CBDA, CSE, Cancer, AIS, Fluid Equipment Development Company, Cannabis, Gene, Artificial intelligence, View, NASDAQ, Interferon beta-1a, Brain, Kinetics, Physics, Solution, THCA, Yeda, CPG, Genetic engineering, Patent, Multimedia, CBGA, API, Weizmann Institute of Science, Gene pool, Income, TEL, CBCA, Prenylation, Cannabis sativa, IP, Institute, Metabolomics, Cannabinoid, Industry, Climate change, Bacteria, Efficiency, Fine chemical, Glatiramer acetate, Science

TEL AVIV, Israel, Sept. 8, 2022 /PRNewswire/ -- Xinteza API Ltd., an innovative biosynthesis technology company, announced today the discovery of a new catalytic enzyme, capable of solving one of the major bottlenecks that has so far limited the design of sustainable and cost-efficient cannabinoid biosynthesis production systems, in breakthrough research led by Prof. Asaph Aharoni at the Weizmann Institute of Science.

Key Points: 
  • As reported previously , Xinteza has recently unveiled discoveries for a patent-pending whole new non-cannabis source of cannabinoid biosynthesis related genes and enzymes.
  • This newly discovered gene pool includes a novel prenyl-transferase enzyme, featuring superior kinetics and improved flexibility in introduction into micro-organism-based expression systems.
  • "As we expand our IP's commercialization and collaboration activity, we are highly motivated by this pivotal discovery of such a key novel enzyme.
  • "We continue to optimize commercial-scale processes of cannabinoid biosynthesis with the most sophisticated proprietary cannabinoid producing genes and enzymes from our growing portfolio", Gal added.

Specialty Generics Market to be Worth $148.7 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, August 30, 2022
Elixir, University, Conditional sentence, Cancer, Program, Oncology, SAN, Solution, Multiple sclerosis, USD, Specialty, Degenerative disease, Glatiramer acetate, Absorption, Prevalence, Arthritis, FDA, CAGR, Revenue, Projection, Hepatitis C, Annual report, Laboratory, Growth, Patient, Pharmaceutical industry, Teriflunomide

SAN FRANCISCO, Aug. 30, 2022 /PRNewswire/ --The global specialty generics market size is expected to reach USD 148.7 billion by 2030, according to a new study by Grand View Research Inc.

Key Points: 
  • SAN FRANCISCO, Aug. 30, 2022 /PRNewswire/ --The global specialty generics market size is expected to reach USD 148.7 billion by 2030, according to a new study by Grand View Research Inc.
  • Key Industry Insights & Findings from the report:
    Based on type, the injectable segment dominated the market in 2021.
  • Read 101-page full market research report, " Specialty Generics Market Size, Share & Trends Analysis Report By Type (Injectables, Oral Drugs), By Application (Oncology, Inflammatory Conditions, Hepatitis C), By End-use (Specialty, Retail), By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global specialty generics market by type, application, end-use, and region:
    Specialty Generics Market- Type Outlook (Revenue, USD Billion, 2018 - 2030)